Enabler cells containing a shortened oncoprotein in early-stage breast cancers could predict which tumors are more aggressive and destined to metastasize, report researchers from Georgetown University.
Neuropathological staging studies have suggested that tau pathology spreads through the brain in Alzheimer’s disease (AD) and other tauopathies, but this study aimed to reveal more about how neuroanatomical connections, spatial proximity, and regional vulnerability affect this process.
The new automation friendly reagents allow laboratories testing for COVID-19 have a tool that allows them to skip the RNA extraction step of the many testing workflows and move directly to PCR amplification.
The meta-analysis, believed to be the largest of its type, reviewed six earlier DNA methylation studies of AD, which represented brain tissue studies of 1,453 individuals.
In the three months since J&J’s COVID-19 vaccine received emergency use authorization from the FDA, more than 10 million Americans have received the vaccine, according to the Centers for Disease Control and Prevention.
While scientists know that tumors accumulate fats and that the accumulation is associated with immune dysfunction, the details of the relationship were not fully understood. The new findings suggest that the tumor microenvironment contains an abundance of oxidized fat molecules that suppress killer T cells’ ability to kill cancer cells when ingested.
Research shows that the gene OTUD7A controls a cancer-causing protein in Ewing sarcoma bone cancer and that it's possible to block the activity of this oncoprotein, revealing a new drug candidate for treating this type of cancer.
Clofazimine, which was discovered in 1954, is FDA approved and on the World Health Organization’s List of Essential Medicines. The drug’s utility for COVID-19 was initially identified by screening more than 12,000 drugs from the ReFRAME drug library.
The researchers examined the proposed link between peroxisome proliferator-activated receptor (PPAR) and how it promotes regeneration and tumorigenesis by enhancing intestinal stem cell numbers, proliferation, and function.
Along with identifying these putative cell of origin for a variety of RCCs, the analysis also revealed pathways and interactions within the tumor microenvironment that predicted whether the tumor would respond to immunotherapy.
With the aid of the n-lorem Foundation, doctors and patients now have hope of finding treatments to the most rare of genetic diseases.
A wider reach—in patients and data—promises better outcomes.
Broader, more diverse genomic data sets allow better training of polygenic risk score algorithms, moving them from research models into the clinic.
This year we highlight a range of leaders in precision medicine ranging from infectious disease experts to CRISPR researchers to company founders.